-
Something wrong with this record ?
Good long-term glycemic compensation is associated with better trabecular bone score in postmenopausal women with type 2 diabetes
P. Jackuliak, M. Kužma, Z. Killinger, J. Payer
Language English Country Czech Republic
Document type Journal Article
NLK
Directory of Open Access Journals
from 1991
Free Medical Journals
from 1998
ProQuest Central
from 2005-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Nursing & Allied Health Database (ProQuest)
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1998
- MeSH
- Diabetes Mellitus, Type 2 blood drug therapy pathology MeSH
- Glycated Hemoglobin metabolism MeSH
- Hypoglycemic Agents pharmacology therapeutic use MeSH
- Drug Therapy, Combination MeSH
- Bone Density * MeSH
- Middle Aged MeSH
- Humans MeSH
- Metformin pharmacology therapeutic use MeSH
- Postmenopause MeSH
- Cross-Sectional Studies MeSH
- Sitagliptin Phosphate pharmacology therapeutic use MeSH
- Cancellous Bone drug effects pathology MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
Osteoporosis is an increasingly widespread disease, as well as diabetes mellitus. It is now accepted that osteoporotic fractures are a serious co-morbidity and complication of diabetes. Despite of good bone mineral density in Type 2 Diabetes (T2DM) patients is the fracture risk elevated. It is due to reduced bone quality. To determine the effect of glycemic compensation on bone density and trabecular bone score (TBS) in T2DM. We analyzed a cohort of 105 postmenopausal women with T2DM. For all patients, central bone density (spinal and lumbar spine) was tested by DXA methodology, glycemic control parameters were assessed, and anthropometric parameters were measured. Bone quality was analyzed using TBS software. The results were statistically processed. Good glycemic compensation with glycated hemoglobin (A1c) value <7.0 % DCCT did not lead to BMD changes in patients with T2DM. However, patients with HbA1c <7 % DCCT had significantly better TBS (1.254±0.148 vs. 1.166±0.094, p=0.01). There was a negative correlation between TBS and glycated hemoglobin (r= -0,112, p<0.05) with glycemic fasting (r= -0.117, p<0.05). The optimal effect on TBS is achieved when all three markers of glycemic compensation (glycated hemoglobin, fasting plasma glucose and postprandial glycemia) are in optimal range. By using ROC curves glycated hemoglobin has the most significant effect on TBS. Optimal glycemic compensation, evaluated by glycated hemoglobin, does not lead to changes in BMD but has a beneficial effect on TBS in T2DM. Good glycemic control is required also for reduction of the risk of osteoporosis and osteoporotic fractures.
References provided by Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21028173
- 003
- CZ-PrNML
- 005
- 20220328142827.0
- 007
- ta
- 008
- 211105s2019 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.934304 $2 doi
- 035 __
- $a (PubMed)31842578
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Jackuliak, Peter, $d 1981- $7 xx0227317 $u 5th Department of Internal Medicine, Faculty of Medicine, Comenius University Bratislava, University Hospital Bratislava, Bratislava, Slovak Republic
- 245 10
- $a Good long-term glycemic compensation is associated with better trabecular bone score in postmenopausal women with type 2 diabetes / $c P. Jackuliak, M. Kužma, Z. Killinger, J. Payer
- 504 __
- $a Literatura
- 520 9_
- $a Osteoporosis is an increasingly widespread disease, as well as diabetes mellitus. It is now accepted that osteoporotic fractures are a serious co-morbidity and complication of diabetes. Despite of good bone mineral density in Type 2 Diabetes (T2DM) patients is the fracture risk elevated. It is due to reduced bone quality. To determine the effect of glycemic compensation on bone density and trabecular bone score (TBS) in T2DM. We analyzed a cohort of 105 postmenopausal women with T2DM. For all patients, central bone density (spinal and lumbar spine) was tested by DXA methodology, glycemic control parameters were assessed, and anthropometric parameters were measured. Bone quality was analyzed using TBS software. The results were statistically processed. Good glycemic compensation with glycated hemoglobin (A1c) value <7.0 % DCCT did not lead to BMD changes in patients with T2DM. However, patients with HbA1c <7 % DCCT had significantly better TBS (1.254±0.148 vs. 1.166±0.094, p=0.01). There was a negative correlation between TBS and glycated hemoglobin (r= -0,112, p<0.05) with glycemic fasting (r= -0.117, p<0.05). The optimal effect on TBS is achieved when all three markers of glycemic compensation (glycated hemoglobin, fasting plasma glucose and postprandial glycemia) are in optimal range. By using ROC curves glycated hemoglobin has the most significant effect on TBS. Optimal glycemic compensation, evaluated by glycated hemoglobin, does not lead to changes in BMD but has a beneficial effect on TBS in T2DM. Good glycemic control is required also for reduction of the risk of osteoporosis and osteoporotic fractures.
- 650 12
- $a kostní denzita $7 D015519
- 650 _2
- $a trabekulární kostní tkáň $x účinky léků $x patologie $7 D000071556
- 650 _2
- $a průřezové studie $7 D003430
- 650 _2
- $a diabetes mellitus 2. typu $x krev $x farmakoterapie $x patologie $7 D003924
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a glykovaný hemoglobin $x metabolismus $7 D006442
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypoglykemika $x farmakologie $x terapeutické užití $7 D007004
- 650 _2
- $a metformin $x farmakologie $x terapeutické užití $7 D008687
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a postmenopauza $7 D017698
- 650 _2
- $a sitagliptin fosfát $x farmakologie $x terapeutické užití $7 D000068900
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kužma, Martin $7 xx0227382 $u 5th Department of Internal Medicine, Faculty of Medicine, Comenius University Bratislava, University Hospital Bratislava, Bratislava, Slovak Republic
- 700 1_
- $a Killinger, Zdenko $7 xx0106789 $u 5th Department of Internal Medicine, Faculty of Medicine, Comenius University Bratislava, University Hospital Bratislava, Bratislava, Slovak Republic
- 700 1_
- $a Payer, Juraj, $d 1958- $7 xx0140923 $u 5th Department of Internal Medicine, Faculty of Medicine, Comenius University Bratislava, University Hospital Bratislava, Bratislava, Slovak Republic
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 68, Suppl 2 (2019), s. S149-S156
- 773 0_
- $t Advances in internal medicine $g (2019), s. S149-S156 $w MED00208905
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31842578 $y Pubmed
- 910 __
- $a ABA008 $b A 4120 $c 266 $y p $z 0
- 990 __
- $a 20211105 $b ABA008
- 991 __
- $a 20220328142825 $b ABA008
- 999 __
- $a ok $b bmc $g 1728775 $s 1148718
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 68 $c Suppl 2 $d S149-S156 $e 20191130 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
- BMC __
- $a 2019 $d S149-S156 $m Advances in internal medicine $x MED00208905
- LZP __
- $b NLK118 $a Pubmed-20211105